Petya Valentinova Peneva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Petya Valentinova Peneva has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Javier Santos
Laboratory of Neuro‐Immuno‐Gastroenterology Digestive System Research Unit Vall d’Hebron Institut de Recerca (VHIR) Vall d’Hebron Hospital Universitari Vall d’Hebron Barcelona Hospital Campus Barcelona Spain
1 shared publication - Jean-Marc Sabaté
Department of Gastroenterology and Digestive Oncology, Hôpital Avicenne, AP‐HP Sorbonne Paris Nord University Bobigny France
1 shared publication - Mariya Armova
Outpatient Clinic for Individual Practice for Primary Medical Care, 4000 Plovdiv, Bulgaria
1 shared publication - Martina Stefanova Nikolova
Medical Center Prolet, 7000 Ruse, Bulgaria
1 shared publication - Petar Martinov Draganov
Medical Center Prolet, 7000 Ruse, Bulgaria
1 shared publication
Latest Publications
- Open Access
- 23 February 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (1) , 19
Efficacy and Safety of Chia Seed Powder, Pea Protein, and Xyloglucan in Patients with Constipation-Predominant Irritable Bowel Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Background/Objectives: Natural compounds represent novel promising alternative treatments for functional gastrointestinal disorders. This multicenter, double-blind, randomized, placebo-controlled, crossover study aimed to evaluate the efficacy and safety of xyloglucan, pea protein, and chia seed powder (XP + CS) in irritable bowel syndrome with constipation (IBS-C). Methods: Sixty patients received twice-daily XP + CS or placebo for 28 days. Following a 28-day washout period, patients switched to the alternative treatment for another 28 days. Efficacy was evaluated using the Bristol Stool Form Scale; a seven-point Likert scale for abdominal pain, bloating, and discomfort; a Visual Analogue Scale for IBS symptom severity; the quality of life (QoL)-IBS questionnaire; Sickness Impact Profile (SIP) score; and serum zonulin concentrations. Adverse events were monitored throughout the study. Results: Compared to the placebo, XP + CS significantly improved stool consistency (p = 0.04 and p < 0.001 at days 15 and 28, respectively), IBS symptoms (p < 0.001 at day 15), QoL (p < 0.001 from day 15 on), and nearly all SIP domains (p < 0.001 at all time-points). Additionally, XP + CS treatment restored serum zonulin concentrations to within normal ranges by day 15. No serious adverse events were reported. Conclusions: This study provides evidence supporting the efficacy and safety of XP + CS in managing IBS-C symptoms.
- 23 February 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (1) , 19
Open AccessEfficacy and Safety of Chia Seed Powder, Pea Protein, and Xyloglucan in Patients with Constipation-Predominant Irritable Bowel Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Background/Objectives: Natural compounds represent novel promising alternative treatments for functional gastrointestinal disorders. This multicenter, double-blind, randomized, placebo-controlled, crossover study aimed to evaluate the efficacy and safety of xyloglucan, pea protein, and chia seed powder (XP + CS) in irritable bowel syndrome with constipation (IBS-C). Methods: Sixty patients received twice-daily XP + CS or placebo for 28 days. Following a 28-day washout period, patients switched to the alternative treatment for another 28 days. Efficacy was evaluated using the Bristol Stool Form Scale; a seven-point Likert scale for abdominal pain, bloating, and discomfort; a Visual Analogue Scale for IBS symptom severity; the quality of life (QoL)-IBS questionnaire; Sickness Impact Profile (SIP) score; and serum zonulin concentrations. Adverse events were monitored throughout the study. Results: Compared to the placebo, XP + CS significantly improved stool consistency (p = 0.04 and p < 0.001 at days 15 and 28, respectively), IBS symptoms (p < 0.001 at day 15), QoL (p < 0.001 from day 15 on), and nearly all SIP domains (p < 0.001 at all time-points). Additionally, XP + CS treatment restored serum zonulin concentrations to within normal ranges by day 15. No serious adverse events were reported. Conclusions: This study provides evidence supporting the efficacy and safety of XP + CS in managing IBS-C symptoms.